Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhinoconjunctivitis with or without controlled bronchial asthma

Trial Profile

Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhinoconjunctivitis with or without controlled bronchial asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Asthma; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Acronyms ASTOR
  • Sponsors Allergopharma
  • Most Recent Events

    • 26 Aug 2017 Status changed from recruiting to completed.
    • 13 Jan 2017 There has been a protocol amendment where the planned number of patients changed from 360 to 120 and the patient age for inclusion has changed from 2-64 to 18-64 .
    • 07 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top